<DOC>
	<DOCNO>NCT00510042</DOCNO>
	<brief_summary>The objective study assess clinical presentation , treatment complication disease treatment moderate severe von Willebrand disease . Another goal investigate influence von Willebrand disease quality life .</brief_summary>
	<brief_title>National Study Moderate Severe Von Willebrand Disease Netherlands</brief_title>
	<detailed_description>The incidence von Willebrand disease Netherlands unknown , occurrence type von Willebrand disease together estimate 1:100-1:200 individual . Most patient mild von Willebrand disease , mostly type 1 . For severe form von Willebrand disease incidence unclear , expectation , least 500-1500 patient . In Netherlands , unique situation exist treatment patient hemophilia related coagulation disorder . In 2000 hemophilia management policy set Ministry Health , state care patient concentrate 13 Hemophilia Treatment Centers ( HTC ) . The representative attend center , hemophilia specialist , organize NVHB , Dutch society Hemophilia treater . In hemophilia management policy state patient coagulation disorder dependent replacement product must treat HTC responsibility HTC . These patient see HTC least year . Because moderate severe von Willebrand patient Netherlands know HTC , possible register study population . This imperative research von Willebrand disease . Because moderate severe form von Willebrand disease rare , impossible individual center perform research moderate severe severe von Willebrand disease . Therefore national approach necessary . For optimal care patient moderate severe form von Willebrand disease well understanding symptom , diagnostics , treatment complication treatment necessary . The present study aim register investigate patient Netherlands moderate severe von Willebrand disease gain understanding clinical presentation , treatment complication treatment moderate severe von Willebrand disease . Another goal investigate influence von Willebrand disease quality life . To answer question questionnaire develop , send study population . In addition , blood drawn von Willebrand factor measurement plasma DNA store . The relationship laboratory parameter , ( include von Willebrand factor , FVIII prothrombotic coagulation disorder ) clinical phenotype patient moderate severe von Willebrand disease study . We assess effect laboratory parameter severity bleed tendency , possible protect effect risk arterial thrombosis . In future mutation analysis VWF gene perform patient moderate severe von Willebrand disease Netherlands .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>1. haemorrhagic symptom family history von Willebrand disease 2. vWF antigen ≤ 30 % , low measurement count and/or vWF activity ( vWF : RCo vWF : CB ) ≤ 30 % , low measurement count and/or FVIII : C ≤ 40 % , low measurement count 3. know hemophilia treatment center diagnose make hemophilia treatment center must do 1987 1 . Hemophilia A 2 . Carriership hemophilia A 3 . No informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>von Willebrand disease</keyword>
	<keyword>von Willebrand factor</keyword>
	<keyword>national study</keyword>
	<keyword>bleed disorder</keyword>
	<keyword>quality life</keyword>
</DOC>